ANXA4 and lung carcinoma: These in vitro results found further support in a preclinical model of lung cancer; in fact, both FHIT gene therapy and annexin A4 depletion acted synergistically with paclitaxel in inducing tumor regression in mice compared to controls; this combination could be of useful interest in the treatment of lung cancer patients.